AAN 2024: Exploring New Horizons in Relapsing-Remitting Multiple Sclerosis Treatment

Michael Sy, MD, PhD

May 09, 2024

Michael Sy, MD, PhD, reflects on the 2024 AAN Annual Meeting and observes a paradigm shift in neurology, particularly in multiple sclerosis (MS) management. While B-cell depletion therapies remain popular, concerns around long-term safety, particularly in pediatric-onset MS, raise questions about their universal applicability.

Exciting developments, such as the identification of new risk genes and the exploration of novel biomarker tests, offer promise for more precise and effective management strategies in MS. Insights into genetics, imaging, and fluid biomarkers provide hope for more accurate management, with a particular focus on relapse prediction. These insights, gleaned from the conference, signal a transformative shift towards individualized patient care in neurology.

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: AAN 2024: Exploring New Horizons in Relapsing-Remitting Multiple Sclerosis Treatment - Medscape - May 09, 2024.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.